Prostate

Article	Citations
VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach	52
Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy	45
Non‐cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy	40
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer	34
	34
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level	31
Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer	27
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review	26
Continuity of care in acute survivorship phase, and short and long‐term outcomes in prostate cancer patients	25
	24
Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐cente	24
	24
Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities	24
The effect of tranexamic acid on perioperative blood loss in transurethral resection of the prostate: A double‐blind, randomized controlled trial	23
Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis	21
A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening	20
3βHSD activity saturates at physiological substrate concentrations in intact cells	20
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide	20
Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity	20
Smoothened loss is a characteristic of neuroendocrine prostate cancer	19
Genetic polymorphisms at 19q13.33 are associated with [−2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer	19
A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer	19
Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer	19
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA‐targeted radioligand therapy	18
Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides	17

Investigation of pelvic floor influence on prostate displacement in image‐guided radiotherapy	17
Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration‐resistant prostate cancer treated with abiraterone or enzalutamide	17
βArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration‐resistant prostate cancer	17
The 28th Annual Prostate Cancer Foundation Scientific Retreat report	16
Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate	16
Impact of definitive radiotherapy on metabolic response measured with 68Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer	16
Intermediate‐term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score	16
Analysis of three primary prostatic sarcoma cases and literature review	16
Strong PD‐L1 expression in granulomatous prostatitis	16
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study	16
Detection of intraductal carcinoma in prostate cancer patients with small tumor volume	15
Tumorigenic transformation of human prostatic epithelial cell line RWPE‐1 by growth hormone‐releasing hormone (GHRH)	15
Clinical and genomic features of SPOP‐mutant prostate cancer	15
SPOP andCHD1alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence	15
Lack of repeatability of radiomic features derived from PET scans: Results from a 18F‐DCFPyL test–retest cohort	15
Lymphocyte‐to‐monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy	15
Characteristics of recurrent acute urinary retention in BPH patients in the United States: Retrospective analysis of US‐based insurance claims database	15
Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining‐targeted biopsy	15
Issue Information	15
Issue Information	14
Overexpression of regucalcin blocks the migration, invasion, and bone metastatic activity of human prostate cancer cells: Crosstalk between cancer cells and bone cells	14
The association between beta‐blockers use and prostate cancer mortality: A mini systematic review and meta‐analysis	14
	14
Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients	14
Issue Information	14
	14
	13
Histologic inflammation and collagen content are not positively correlated in human BPH	13
Artificial intelligence trained with integration of multiparametric MR‐US imaging data and fusion biopsy trajectory‐proven pathology data for 3D prediction of prostate cancer: A proof‐of‐concept study	13
Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy	13
Value of synthetic MRI quantitative parameters in preprocedural evaluation for TRUS/MRI fusion‐guided biopsy of the prostate	13
Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population	13
Image‐guided multiparametric magnetic resonance imaging‐transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, c	13
The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot‐assisted laparoscopic radical prostatectomy	13
Aqueous metabolome of tissue‐specific conditional Pten‐knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma	12
Issue Information	12
Joint effect between bisphenol A and alcohol consumption on benign prostatic hyperplasia: A case–control study in Hong Kong Chinese males	12
Paracrine Wnt signaling is necessary for prostate epithelial proliferation	12
Three‐dimensional ultrastructural and anatomical analysis of prostatic neuroendocrine cells in mice	11
Real‐world analysis of metastatic prostate cancer demonstrates increased frequency of PSA‐imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy	11
Feasibility and preliminary clinical tolerability of low‐field MRI‐guided prostate biopsy	11
Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy	11
Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing	11
Emotion‐centered versus fact‐centered medical information to alleviate pain and anxiety in prostate biopsy: A randomized trial	11
Proapoptotic effect of nonthermal pulsed ultrasound on prostate cancer cells in a nude mouse model	11
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations	11
Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2‐ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE‐UERJ	11
Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy	11
Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation	10
Factors impacting on sexual function among men on active surveillance for prostate cancer	10

Impact of mpMRI targeted biopsy on intraoperative nerve‐sparing (NeuroSAFE) during robot‐assisted laparoscopic radical prostatectomy	10
Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost‐effective?	10
The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases	10
PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer	10
Cover Image: Volume 83 Issue 2	10
Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach	10
	10
Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume	10
Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial	10
Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration‐resistant prostate cancer	10
Issue Information	9
Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers	9
Quality of life outcomes for patients with metastatic castration‐resistant prostate cancer and pretreatment prognostic score	9
Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high‐risk localized prostate cancer	9
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen‐induced transcriptional response in prostate cancer	9
Issue Information	9
A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate‐Resistant Prostate Cancer (TRICREST)	9
Coconut Oil Mitigates the Effects of Aging on the Mongolian Gerbil Prostate	9
Racial differences in circulating mitochondria‐derived peptides may contribute to prostate cancer health disparities	9
Nomograms for detecting lymph node metastasis detected with surgery—Can you name any birds other than crow?	9
ERG and PTEN Role on Active Surveillance for Low‐Risk Prostate Cancer in the Multiparametric MRI Era	9
Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p‐STAT3 in prostate cancer	9
Influence of androgen deprivation therapy on the severity of COVID‐19 in prostate cancer patients	9
Prognostic role of pan‐immune‐inflammation value in patients with metastatic castration‐resistant prostate cancer treated with androgen receptor‐signaling inhibitors	9
Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms	9
	9
Erratum to “Differential Impact of Paired Patient‐Derived BPH and Normal Adjacent Stromal Cells on Benign Prostatic Epithelial Cell Growth in 3D Culture”	9
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting	9
	9
Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms	9
Key learnings from concordant systematic biopsies in prostate‐specific membrane antigen positron emission tomography/computed tomography‐guided prostate biopsies: Enhancing targeting accuracy	9
	9
	9
Proteoglycans orchestrate remodeling of prostatic cytoarchitecture after androgenic blockade in old gerbils	8
Clinical and histopathological parameters in transrectal ultrasound‐guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups	8
Pathological significance and prognostic role of LATS2 in prostate cancer	8
Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk	8
The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy	8
Polyphyllin I induces ferroptosis in castration‐resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis	8
Long‐term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life‐table data	8
First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer	8
Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era	8
Comparison of Prognosis and Health‐Related Quality of Life Between Robot‐Assisted Radical Prostatectomy Versus High‐Dose‐Rate Brachytherapy Combined With External Beam Radiation Therapy and Hormone Th	8
Diagnosis and management of neuroendocrine prostate cancer	8
Physician knowledge, practice patterns, and barriers encountered regarding guideline‐concordant use of bone modifying agents for prostate cancer	8
SLX4IP N‐terminus dictates telomeric localization in ALT‐like castration‐resistant prostate cancer cell lines	8
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients	8
Stratification of prostate cancer patients into low‐ and high‐grade groups using multiparametric magnetic resonance radiomics with dynamic contrast‐enhanced image joint histograms	8
Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI	8
Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples	8
Rates and trends in stage‐specific prostate cancer incidence by age and race/ethnicity, 2000–2017	8
	8
Clinical utility of the prognostic nutritional index in patients with metastatic hormone‐sensitive prostate cancer: A retrospective, multicenter, cohort study	8
Does surgery benefit patients with oligometastatic or metastatic prostate cancer? – A retrospective cohort study and meta‐analysis	8
Response to the letter to the editor: “Don't throw the baby out with the bath water” by Horsley et al.	8
Patient‐reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy‐monitored study	8
Evaluating the Heterogeneity of Advanced Prostate Cancer by 18F‐DCFPyL and 18F‐FDG PET/CT in a Prospective Cohort	8
Issue Information	8
Prostate cancer focal therapy: surgeon experience influences oncological results	8
Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy	8
Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers	8
Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer	8
Head‐to‐head comparison of GA‐68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer	8
Safety and Efficacy of Intra‐Prostatic Injection of Betamethasone for Refractory Chronic Nonbacterial Prostatitis: A Prospective Cohort Clinical Study	7
Issue Information	7
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality	7
Radiographic paradoxical response in metastatic castrate‐resistant prostate cancer (mCRPC) managed with new generation anti‐androgens: a retrospective analysis	7
Therapeutic effects of nerve growth factor‐targeting therapy on bladder overactivity in rats with prostatic inflammation	7
The 30th Annual Prostate Cancer Foundation Scientific Retreat Report	7
Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis	7
Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?	7
Issue Information	7
Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer	7
Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer	7
Development of a novel castration‐resistant orthotopic prostate cancer model in New Zealand White rabbit	7
Risk factors for bladder neck contracture after transurethral resection of the prostate	7
Chronic coexposure to arsenic and estrogen potentiates genotoxic estrogen metabolic pathway and hypermethylation of DNA glycosylase MBD4 in human prostate epithelial cells	7
Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real‐life experience of ADT in Asia (READT) study	7
Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL‐17 signaling pathway gene LCN2 in castration‐resistant prostate cancer	7
Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound	7

ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis	7
Barriers and facilitators of germline genetic evaluation for prostate cancer	7
Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratificatio	7
Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate	7
Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer	7
Don't throw the baby out with the bath water	7
Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacoth	7
The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer	7
	7
Combined 177Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing t	6
Issue Information	6
	6
	6
Evidence for a causal effect of major depressive disorder, anxiety on prostatitis risk: A univariate and multivariate Mendelian randomization study	6
Are higher pre‐diagnosis follicle stimulating hormone levels associated with long‐term prostate cancer risk?	6
Histologically benign PI‐RADS 4 and 5 lesions contain cancer‐associated epigenetic alterations	6
Overall and metastasis‐free survival of Afro‐Caribbean patients with biochemical recurrence after radical prostatectomy	6
Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin	6
Salvage stereotactic reirradiation for intraprostatic cancer recurrence: A large retrospective study	6
Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer	6
An update on the current status and future prospects of erectile dysfunction following radical prostatectomy	6
Evaluation of a photodynamic therapy agent using a canine prostate cancer model	6
Issue Information	6
External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high‐grade prostate cancer patients	6
	6
Other‐cause mortality in incidental prostate cancer	6
IU1 and enzalutamide combination yields synergistic effects on castration‐resistant prostate cancer	6
Ten‐year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot‐assisted radical prostatectomy	6
Glycoforms of human prostate‐specific membrane antigen (PSMA) in human cells and prostate tissue	6
Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy	6
Effects of cycling and rowing on serum concentrations of prostate‐specific antigen: A randomized study of 101 male subjects	6
Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis	6
Phenotypic characterization of two novel cell line models of castration‐resistant prostate cancer	6
Issue Information	6
The activated complement pathway in the fibrous process of benign prostatic hyperplasia	6
Issue Information	6
	6
Cover Image: Volume 83 Issue 3	6
Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer	6
Advanced glycation end‐products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry	6
Long‐term outcomes of radical prostatectomy versus low‐dose‐rate brachytherapy in patients with intermediate‐risk prostate cancer: Propensity score matched comparison	6
Long term update on toxicity and survival of a phase II trial of linac‐based stereotactic body radiation therapy for low‐intermediate risk prostate cancer	6
Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience	6
Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer	6
Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer	5
Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer	5
Identification of novel susceptibility factors related to CP/CPPS‐like symptoms: Evidence from a multicenter case‐control study	5
The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement	5
The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases	5
SIRT3 affects mitochondrial metabolic reprogramming via the AMPK–PGC‐1α axis in the development of benign prostatic hyperplasia	5
Reply to Letter to the Editor on “Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients”	5
Prostate‐specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma	5
Application of European‐specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations	5
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration‐resistant prostate cancer patients	5
Co‐targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis	5
The cribriform morphology impairs Gleason 7 prostate cancer lesion detection on multiparametric magnetic resonance imaging	5
Conditional survival does not improve over time in metastatic castration‐resistant prostate cancer patients undergoing docetaxel	5
CTPC, a combined transcriptome data set of human prostate cancer cell lines	5
Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study	5
Does castration status affect docetaxel‐related adverse events? :Identification of risk factors for docetaxel‐related adverse events in metastatic prostate cancer	5
Hormonal and genotoxic estrogen‐androgen carcinogenesis in the NBL rat prostate: A role for aromatase	5
Microultrasound in the detection of the index lesion in prostate cancer	5
Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors	5
Significance of extraprostatic extension by Grade Groups 1–3 prostatic carcinoma on needle biopsy	5
Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy	5
Prostate cancer grade downgrading at time of prostatectomy provides risk‐stratification insight into future tumor behavior after prostatectomy	5
The 27th Annual Prostate Cancer Foundation Scientific Retreat Report	5
Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen depriva	5
Issue Information	5
ATF6α promotes prostate cancer progression by enhancing PLA2G4A‐mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis	5
Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer	5
Association of germline rare pathogenic mutations in guideline‐recommended genes with prostate cancer progression: A meta‐analysis	5
Prostate Cancer Classification and Interpretation With Multiparametric Magnetic Resonance Imaging and Gleason Grade Score Using DarkNet53 Model	5
Cancer cells employ lipid droplets to survive toxic stress	5
Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer	5
18F‐sodium fluoride positron emission tomography quantitation of bone metastases in African American and non‐African American men with metastatic prostate cancer	5
Issue Information	5
Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer	5
Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells	5
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancer	5
	5
A CXCR4 inhibitor (balixafortide) enhances docetaxel‐mediated antitumor activity in a murine model of prostate cancer bone metastasis	5
The role of histopathological and biochemical parameters for predicting metastatic disease on 68Ga‐PSMA‐11 PET in prostate cancer	4
Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer	4
Relationship Between Radiation Therapy and Fecal Incontinence in Patients Treated for Localized Prostate Cancer: Results of the French ICONES Study	4
Life Expectancy in High‐Grade Incidental Prostate Cancer Patients Versus Population‐Based Controls According to Treatment Type	4
Prognostic role of 11C‐choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy	4
FOXA1 regulates ribosomal RNA transcription in prostate cancer	4
Effect of type of definitive treatment on race‐based differences in prostate cancer‐specific survival	4
Future directions for precision oncology in prostate cancer	4
Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long‐term follow‐up study	4
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients	4
Impact of COVID‐19 on the progression of benign prostatic hyperplasia and aggravation of related symptoms: A prospective study	4
Metagenomics studies for the diagnosis and treatment of prostate cancer	4
Stimulated Raman histology, a novel method to allow for rapid pathologic examination of unprocessed, fresh prostate biopsies	4